Standout Papers

Empagliflozin, Cardiovascular Outcomes, and Mortality in T... 2008 2026 2014 2020 7.8k
  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015)
    Bernard Zinman, Christoph Wanner et al. New England Journal of Medicine
  2. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes (2016)
    Christoph Wanner, Silvio E. Inzucchi et al. New England Journal of Medicine
  3. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus (2013)
    David Z.I. Cherney, Bruce A. Perkins et al. Circulation
  4. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients (2014)
    Ele Ferrannini, Elza Muscelli et al. Journal of Clinical Investigation
  5. Adipokines and Insulin Resistance (2008)
    Michael Lehrke, Klaus G. Parhofer et al. Molecular Medicine
  6. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (2014)
    Anthony Barnett, Ambrish Mithal et al. The Lancet Diabetes & Endocrinology
  7. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus (2014)
    David Z.I. Cherney, Bruce A. Perkins et al. Cardiovascular Diabetology
  8. Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension (2014)
    Ilkka Tikkanen, Kirsi Narko et al. Diabetes Care
  9. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes (2015)
    Robert Ćhilton, I. Tikkanen et al. Diabetes Obesity and Metabolism
  10. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease (2017)
    Christoph Wanner, John M. Lachin et al. Circulation
  11. Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial (2014)
    Hans‐Ulrich Häring, Ludwig Merker et al. Diabetes Care

Immediate Impact

1 from Science/Nature 122 standout
Sub-graph 1 of 14

Citing Papers

Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease
2022 Standout
Gliflozins in the Management of Cardiovascular Disease
2022 Standout

Works of Uli C. Broedl being referenced

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Uli C. Broedl 18132 8994 8145 117 22.4k
Odd Erik Johansen 14296 6166 5659 118 17.1k
David Fitchett 12416 6610 5125 198 18.0k
Ofri Mosenzon 12734 4655 5245 140 15.1k
Michaela Mattheus 11062 4754 4439 80 13.1k
Johannes F.E. Mann 13170 5887 4920 275 28.7k
David Z.I. Cherney 10214 4801 3528 323 14.1k
Irene Stratton 15861 4571 3605 138 23.7k
Hans J. Woerle 11126 5444 5008 88 12.9k
Katherine R. Tuttle 7969 3409 3519 291 18.4k
Stefan Hantel 9082 4555 3893 62 13.3k

All Works

Loading papers...

Rankless by CCL
2026